Safety aspects of long-term nitrendipine therapy.
More than 1,700 patients with essential or renal hypertension were treated with nitrendipine; data from 967 of these were included in a data pool, and safety data were evaluated. Treatment duration was between 7 days and 2 years. The most frequent side-effects were headache, flush, oedema, dizziness, and palpitations due to the pharmacodynamic effect of the drug. All other side-effects had an incidence below 2%. Eighty-two of the 967 patients stopped therapy before the end of the trial. In 33 of these patients, this was probably due to the side-effects of nitrendipine. Hematological and clinical chemistry data did not indicate any systemic or organ damage. When nitrendipine was combined with thiazides, a lowering of plasma potassium levels could be found, which, however, did not necessitate any therapy.
D002121:Calcium Channel Blockers / Q000009:adverse effects* / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D004562:Electrocardiography; D006801:Humans; D006852:Hydrochlorothiazide / Q000009:adverse effects; D006977:Hypertension, Renal / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009568:Nitrendipine; D011188:Potassium / Q000097:blood; D013997:Time Factors; D014527:Uric Acid / Q000097:blood
D002121:Calcium Channel Blockers; D006852:Hydrochlorothiazide; D014527:Uric Acid; D009568:Nitrendipine; D009543:Nifedipine; D011188:Potassium